Irinotecan hydrochloride
General properties
Antineoplastic agents.
Treatment of patients with advanced colorectal cancer:
- In combination with 5-fluorouracil and folinic acid - for patients who have not previously received chemotherapy for the treatment of a common disease;
- As monotherapy - for patients in whom treatment with 5-fluorouracil was ineffective.
In combination with cetuximab, "Irinotecan hydrochloride" is used to treat metastatic colorectal cancer with a wild type KRAS gene that expresses epidermal growth factor receptors to patients who have not previously received metastatic cancer treatment or for whom cytotoxic treatment with irinotecan has been ineffective.
In combination with 5-fluorouracil, folinic acid and bevacizumab, "Irinotecan hydrochloride" is used as first-line therapy for patients with metastatic carcinomas of the colon or rectum.
In combination with capecitabine (with or without bevacizumab), "Irinotecan hydrochloride" is used as first-line therapy for patients with metastatic colorectal cancer.
Presence in the anamnesis of severe hypersensitivity reactions to irinotecan hydrochloride trihydrate or to any of the auxiliary components of the preparation "Irinotecan hydrochloride". Chronic inflammatory bowel disease and / or intestinal obstruction (see section "Features of application"). The period of breastfeeding. The level of bilirubin is more than 3 times higher than the upper limit of the norm. Severe bone marrow failure. Health status by WHO index> 2. Concomitant treatment of St. John's Wort. Vaccination against yellow fever (see section "Interaction with other drugs and other interactions").
Pharmaceutical characteristics
Clear solution of light yellow color.
Store in the original packaging at a temperature not exceeding 30 °C. Keep out of the reach of children.
